There is a paucity of evidence to support that screening interventions conclusively have patient benefits, even in the face of increasing funding for these activities by employers and the government.
Ponte Vedra Beach, Florida (PRWEB) April 25, 2013
This week’s top news story on HealthEconomics.Com related to yet another rejection by the National Institute for Health and Care Excellence (NICE) for Roche’s Avastin (bevacizumab) for advanced ovarian cancer. NICE is the agency tasked with appraising cost-effectiveness of medicines for use in the National Health Service for England and Wales. Issuing its second draft guidance in a month, NICE turned down Avastin for use in combination with gemcitabine and carboplatin in patients with recurrent cancer that has spread outside the ovaries following initial treatment. Only a few weeks prior, NICE rejected Avastin for use in combination therapy with paclitaxel and carboplatin for patients with metastatic ovarian cancer. This most recent rejection occurred according to NICE because Roche failed to provide trial data on approximately one-third of clinical trial participants. If these lack of data were due to drug discontinuation, side effects, or lost to follow-up, then NICE suggested it was difficult to ascertain the effect of Avastin on progression-free survival rates, as well as whether it could in fact help individuals live longer. Without these critical data elements, the cost-effectiveness of the £25,000 per single course of treatment could not adequately be evaluated. Original story published by PMLive.Com.
The second most read story, derived from the HealthEconomics.Com blog: tHEORetically Speaking, features guest blogger Nick Emptage. In a story titled: “The Problem with Preventative Medicine,” Emptage challenges whether preventive medicine could truly solve health care's cost crisis. There is a paucity of evidence to support that screening interventions conclusively have patient benefits, even in the face of increasing funding for these activities by employers and the government. Emptage evaluates the high costs associated with preventative screening in order to detect a small number of events, as well as the effect of patients living longer on total health care costs. While not discouraging preventive care, Emptage accurately points out that a more accurate value assessment is clearly needed before wide-scale government subsidies are implemented.
Another popular news item on HealthEconomics.Com described a new open-access patient registry by PatientCrossRoads, a for-profit organization that helps disease organizations become Registry Partners to better enable disease data collection on rare and common diseases. The story, originally in the Rare Disease Report, featured a video interview with CEO Kyle Brown.
About HealthEconomics.Com (http://www.healtheconomics.com): A pioneer in the field, HealthEconomics.Com is the global authority in healthcare value and pharma market access. Each day, HealthEconomics.Com compiles the latest news, policy updates, resources, conferences, and jobs for BioPharma’s professionals involved in health economics, outcomes research, market access, and pricing. A trusted resource, HealthEconomics.Com’s comprehensive content is carefully selected by a discerning health economist editor, making it the most visited website for healthcare value and market access in the industry, with visitors encompassing all corners of the globe.
News Media interested in receiving the most current information on healthcare value and market access may obtain a free subscription to HealthEconomics.Com by visiting the site or by subscribing to the HealthEconomics.Com Newsletter.